Potential breakthrough for T-Cell lymphoma patients with drug that mimics folic acid

Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL).

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news148062429.html">Potential breakthrough for T-Cell lymphoma patients with drug that mimics folic acid</a></p> <p>Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL).</p>